Sharon A Nachman
Johns Hopkins University, MD·Medicine & Clinical Research
HIV treatment has advanced far faster for non-pregnant adults than for the groups that need it most in many parts of the world: pregnant and postpartum women, infants, children and adolescents. Drug doses, safety margins and side effects differ in a growing child or during pregnancy, so medicines licensed for adults cannot simply be handed down.
- Fields
Medicine & Clinical Research
Public Health & Epidemiology
Microbiology & Immunology
- Topics
pediatric HIV
perinatal HIV
antiretroviral therapy
- Grants
- 1 known grant, through Nov 2027
What they work on
- Advance antiretroviral therapy for pregnant and postpartum women with HIV and accelerate pharmacokinetic, safety and antiviral efficacy evaluation of potent, durable antiretroviral drugs for women, infants, children and adolescents toward licensure and correct dosing.
- Test whether therapy-free remission is achievable in infants, children and adolescents with HIV through interventions that prevent, clear or control the viral reservoirs that persist during antiretroviral treatment.
- Evaluate new approaches to preventing, diagnosing and treating tuberculosis in pregnant and postpartum women and in infants, children and adolescents with and without HIV, to establish optimal dosing and regimens.
- Determine feasible methods for preventing and managing the co-infections and complications of HIV and its treatment in pregnant and postpartum women and in young people.
- Conduct phase I through IV trials at clinical research sites in Africa, Asia and the Americas, embedding socio-behavioral and pharmacometric methods and developing protocols with community input.
More about the research
This grant supports the leadership of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, whose aim is to find treatments and prevention strategies that are safe, acceptable and workable for these populations and could bring the epidemic among them to an end.
Why it matters
Pregnant women, infants, children and adolescents with HIV often wait years after adults for correctly dosed, well-tolerated medicines. Trials run through this network generate the pharmacokinetic and safety evidence needed to license antiretroviral and tuberculosis drugs for these groups, test whether children might one day control HIV without daily therapy, and define care for the co-infections and complications that most affect them in Africa, Asia and the Americas.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
George Yendewa
Case Western Reserve University, OH·Medicine & Clinical Research
Enroll participants at clinical sites in Cleveland, Cincinnati and Kampala into AIDS Clinical Trials Group treatment trials on antiretroviral drugs, inflammation and organ damage, HIV cure, tuberculosis and hepatitis.
Ahizechukwu Eke
Johns Hopkins University, MD·Medicine & Clinical Research
Assess whether dolutegravir-based antiretroviral therapy (TLD) is associated with metabolic syndrome risk in a prospective cohort of pregnant and postpartum women living with HIV and their offspring at four sites in the US and Nigeria.
Jerrold Ellner
Rutgers University-New Brunswick, NJ·Medicine & Clinical Research
Scout promising early-stage TB diagnostics and develop a stepwise evaluation plan for each, supported by an Analytic Laboratory Core that assesses and optimizes new technologies.
The school
Johns Hopkins University: 100 labs on PI Pages, $4.1B a year on research, 622 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.